(19)
(11) EP 3 701 956 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.07.2024 Bulletin 2024/29

(45) Mention of the grant of the patent:
26.06.2024 Bulletin 2024/26

(21) Application number: 18870872.1

(22) Date of filing: 14.05.2018
(51) International Patent Classification (IPC): 
A61K 33/00(2006.01)
A61K 9/00(2006.01)
 A61P 25/28(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 33/00; A61P 25/28; A61K 9/007
(86) International application number:
PCT/JP2018/018483
(87) International publication number:
WO 2019/082428 (02.05.2019 Gazette 2019/18)

(54)

PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DEMENTIA

PROPHYLAKTISCHES UND/ODER THERAPEUTISCHES MITTEL BEI DEMENZ

AGENT PROPHYLACTIQUE ET/OU THÉRAPEUTIQUE CONTRE LA DÉMENCE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 27.10.2017 JP 2017208376

(43) Date of publication of application:
02.09.2020 Bulletin 2020/36

(73) Proprietor: H2 Global Group s.r.o.
Muglinov 712 00 Ostrava (CZ)

(72) Inventors:
  • ONO, Hirohisa
    Numazu-shi Shizuoka 4100022 (JP)
  • NISHIJIMA, Yoji
    Numazu-shi Shizuoka 4100022 (JP)
  • OHTA, Shigeo
    Kawasaki-shi Kanagawa 211-0004 (JP)
  • ASADA, Takashi
    Tokyo 113-0034 (JP)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)


(56) References cited: : 
EP-A1- 1 946 762
JP-A- 2009 114 084
JP-A- 2015 183 005
US-A1- 2015 272 867
 EP-B1- 1 946 762
JP-A- 2009 114 084
JP-A- 2018 030 804
   
  • CAI WANG ET AL: "Hydrogen-rich saline reduces oxidative stress and inflammation by inhibit of JNK and NF-B activation in a rat model of amyloid-beta-induced Alzheimer's disease", NEUROSCIENCE LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 491, no. 2, 7 January 2011 (2011-01-07), pages 127 - 132, XP028145405, ISSN: 0304-3940, [retrieved on 20110114], DOI: 10.1016/J.NEULET.2011.01.022
  • LI J ET AL: "Hydrogen-rich saline improves memory function in a rat model of amyloid-beta-induced Alzheimer's disease by reduction of oxidative stress", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1328, 30 April 2010 (2010-04-30), pages 152 - 161, XP026999980, ISSN: 0006-8993, [retrieved on 20100219]
  • RYUJI YONAMINE ET AL: "Coadministration of Hydrogen Gas as Part of the Carrier Gas Mixture Suppresses Neuronal Apoptosis and Subsequent Behavioral Deficits Caused by Neonatal Exposure to Sevoflurane in Mice", ANESTHESIOLOGY, vol. 118, no. 1, 1 January 2013 (2013-01-01), pages 105 - 113, XP055178856, ISSN: 0003-3022, DOI: 10.1097/ALN.0b013e318275146d
  • KIYOMI NISHIMAKI ET AL: "Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment", CURRENT ALZHEIMER RESEARCH, vol. 15, no. 5, 14 March 2018 (2018-03-14), NL, pages 482 - 492, XP055661340, ISSN: 1567-2050, DOI: 10.2174/1567205014666171106145017
  • KYOTA FUJITA ET AL: "Therapeutic Approach to Neurodegenerative Diseases by Medical Gases: Focusing on Redox Signaling and Related Antioxidant Enzymes", OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. 2012, 1 January 2012 (2012-01-01), US, pages 1 - 9, XP055631635, ISSN: 1942-0900, DOI: 10.1155/2012/324256
  • CHENG-LIN LIU ET AL: "Hydrogen therapy: from mechanism to cerebral diseases", MEDICAL GAS RESEARCH, vol. 6, no. 1, 1 March 2016 (2016-03-01), London, UK, pages 48 - 54, XP055596903, ISSN: 2045-9912, DOI: 10.4103/2045-9912.179346
  • CHENG, LIN-LIU: "Hydrogen therapy: from mechanism to cerebral diseases", MEDICAL GAS RESEARCH, vol. 6, no. 1, March 2016 (2016-03-01), pages 48 - 54, XP055596903
  • OHTA, SHIGEO ET AL.: "Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications", CURRENT PHARMACEUTICAL DESIGN, vol. 17, 2011, pages 2241 - 2252, XP055535704, DOI: 10.2174/138161211797052664
  • SHIGEO OTA: "5. Ninshishō no yobō [Prevention of dementia]", NEWSLETTER, vol. 1, 2010, pages 1 - 4, XP009520108, Retrieved from the Internet <URL:http://www2.nms.ac.jp/ig/soudan/hpb/pdf/Newsletter1012.pdf>
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).